GlassScriptPhysician profile
January L Moennig
NPI 1235182478
$1,020.34
in general payments reported to CMS, 2019-2025
9 companies · $470 in 2025
The $470 reported for 2025 was more than what 75% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $98.33 · 2020: $44.10 · 2021: $267 · 2023: $13.26 · 2024: $127 · 2025: $470.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $480 · Entertainment: $130.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $480.36 |
| Entertainment | $130.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $287.08 | 2019-2025 | Voyager Dslt, Hydrus Microstent, Tryptyr |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $134.37 | 2021 | |
| Hoffmann-La Roche Limited | $133.01 | 2021 | |
| Optos, INC. | $130.17 | 2025 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Ocular Therapeutix, INC. | $127.40 | 2024 | Dextenza |
| Bausch & Lomb Americas INC. | $98.67 | 2025 | Miebo, Xiidra |
| Abb Con-Cise Optical Group LLC | $72.57 | 2019-2023 | Contact Lens, Spectacle Lenses |
| Shire North American Group INC | $22.70 | 2019 | |
| Coopervision INC. | $14.37 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw January Moennig listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.